Clinical trial
A Double-blind, Randomized, Placebo-controlled, Multi-center, Phase III Study to Evaluate the Efficacy and Safety of DWP450 in Japanese Subjects With Moderate to Severe Glabellar Lines
NCT07783763 is registered in ClinicalTrials.gov with Daewoong Pharmaceutical Co. LTD. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Double-blind, Randomized, Placebo-controlled, Multi-center, Phase III Study to Evaluate the Efficacy and Safety of DWP450 in Japanese Subjects With Moderate to Severe Glabellar Lines
- Lead sponsor
- Daewoong Pharmaceutical Co. LTD.
- Phase
- Phase 3
- Overall status
- Not yet recruiting
- Start date
- January 31, 2027
- Completion date
- December 31, 2028
- Enrollment
- 120 (estimated)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.
glabellar lines